Key Points
- Elvia Cowan, Vaxcyte's senior vice president, sold 11,623 shares at an average price of $47.92 for about $556,974, cutting her direct stake by 44.44% to 14,534 shares.
- Vaxcyte missed quarterly earnings with EPS of ($1.56) versus consensus ($1.27), and analysts forecast a -4.21 EPS for the current fiscal year; the stock opened at $46.57 and has a 52‑week range of $27.66–$93.77.
- Wall Street sentiment is broadly positive with a consensus rating of "Moderate Buy" and an average price target of $97.83, while the company carries a market cap of about $6.1 billion.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) SVP Elvia Cowan sold 11,623 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president directly owned 14,534 shares in the company, valued at $696,469.28. This represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Vaxcyte Stock Down 0.9%
Vaxcyte stock opened at $46.57 on Tuesday. The stock has a 50-day moving average price of $45.57 and a 200 day moving average price of $38.40. The company has a market capitalization of $6.10 billion, a price-to-earnings ratio of -9.62 and a beta of 1.28. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $93.77.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.29). During the same period in the prior year, the firm earned ($0.83) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on PCVX shares. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the company an "outperform" rating in a report on Wednesday, November 19th. BTIG Research restated a "buy" rating and issued a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vaxcyte in a research report on Tuesday, October 14th. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, September 12th. They issued a "neutral" rating and a $38.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $97.83.
Check Out Our Latest Report on PCVX
Hedge Funds Weigh In On Vaxcyte
A number of large investors have recently bought and sold shares of PCVX. AlphaQuest LLC purchased a new position in Vaxcyte during the first quarter worth approximately $33,000. Allworth Financial LP raised its stake in shares of Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company's stock worth $44,000 after buying an additional 731 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Vaxcyte during the 3rd quarter worth approximately $45,000. CIBC Private Wealth Group LLC lifted its position in shares of Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company's stock valued at $49,000 after buying an additional 1,350 shares in the last quarter. Finally, CWM LLC grew its stake in Vaxcyte by 197.3% in the 2nd quarter. CWM LLC now owns 1,680 shares of the company's stock valued at $55,000 after acquiring an additional 1,115 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
